Lasofoxifene Monotherapy Induces Durable Complete Remission in a Patient with Estrogen Receptor-Positive, Metastatic Breast Cancer with an ESR1 Mutation

JCO Precis Oncol. 2023 Sep:7:e2300097. doi: 10.1200/PO.23.00097.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Breast Neoplasms* / drug therapy
  • Breast Neoplasms* / genetics
  • Breast Neoplasms* / pathology
  • Female
  • Humans
  • Mutation
  • Pyrrolidines
  • Receptors, Estrogen / genetics

Substances

  • Lasofoxifene
  • Pyrrolidines
  • Receptors, Estrogen